DBP and B-cell chronic lymphocytic leukemia: To assess whether our cell line findings could be recapitulated in primary CLL cells from treatment-naive patients, we used PBMCs from 28 patients with CLL with various disease characteristics (Supplemental Table 1), treated the cells ex vivo with OA, FTY720, and/or venetoclax, and performed DBP, Western blotting, cell viability testing, and co-IP (Figure 12A).